VEDL yields 42.08% · ABBV yields 3.06%● Live data
📍 VEDL pulled ahead of the other in Year 1
Combined, VEDL + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VEDL + ABBV for your $10,000?
Vedanta Limited operates as a diversified natural resources company in India. The company explores for, develops, produces, processes, and sells oil and gas, zinc, lead, silver, copper, aluminum, iron ore, steel, and power. It is involved in the exploration, development, and production of oil and gas; and exploration, mining, and processing of iron ore, pig iron, and metallurgical coke. The company also operates a thermal coal- based commercial power facility of 600 megawatts (MW) at Jharsuguda in the State of Odisha in eastern India; a 300 MW thermal coal based power plant at Korba; 1,980 MW (three units of 660 MW each) thermal coal- based commercial power facilities; 274MW of wind power plants; and a power plant situated at Mettur Dam in the state of Tamil Nadu in southern India. In addition, it manufactures and supplies billets, TMT bars, wire rods, and ductile iron pipes; engages in the mechanization of coal handling facilities and upgradation of general cargo berth for handling coal at the outer harbour of Visakhapatnam Port on the east coast of India; and provides logistics and other allied services inter alia rendering stevedoring, and other allied services in ports and other allied sectors. Further, the company is involved in manufacturing glass substrates in South Korea and Taiwan. It also has operations in South Africa, Namibia, Ireland, Australia, Liberia, and the United Arab Emirates. The company was incorporated in 1965 and is based in Mumbai, India.
Full VEDL Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.